… cardiovascular events (MACEs), whether apoA-1 contributes to this association, and whether
abnormal values occur decades before such events … major anti-atherogenic role, the apoA-…

… Nevertheless, knowing whether anti-apoA-1 IgG could predict poor CV outcome following
… prognostic value of antiapoA-1 IgG to predict major adverse cardiovascular events (MACE) …

… In conclusion, anti-apoA-1 IgG levels are independently associated with CVD in the general
… of anti-ApoA-1 IgG levels over time (38) and especially after cardiovascular events, a point …

… The rate of major adverse cardiovascular events was higher in those with lower levels of
ApoA… -I in patients7,10–14 and improve our understanding of this naturally occurring anti-ApoA-I …

… anti-ApoA-I IgG predicts vascular disease progression and incident cardiovascular events in
… or stroke, selected from the MDC-CV population study. In this apparently healthy cohort, we …

… The primary outcome of this study consisted of major adverse CV events (MACE), defined
… Furthermore, due to the small number of events in this last 23% portion of anti-apoA-I IgG …

… to cardiovascular disease (CVD). A high apolipoprotein (apo)B/apoA1 ratio is known to …
cardiovascular events (CVEs) in the population. apoA1 has, besides anti-atherogenic effects, anti…

… (a) is a risk factor for cardiovascular events and modifies the … (a) concentrations and
cardiovascular events in a high-risk … ) tests for major adverse cardiovascular events (mace). …

… between the serum levels of anti-oxLDL IgG and cardiovascular events was detected (46).
In … Considering atherosclerotic inflammatory processes, we also showed that antiapoA-1 IgG …

… of 362 first cardiovascular events occurred during 7.9 years of follow-up. All pro- and anti-…
or the apolipoprotein B/apolipoprotein AI (apoB/apoA-I) ratio. Ratios are presented in quartiles …